Secondary Urethral Malignancies Following Prostate Brachytherapy

Area of Science:

• Urology
• Oncology
• Radiation Oncology

Background:

• Prostate brachytherapy (BRT) is a common treatment for prostate cancer.
• Secondary malignancies can arise after radiation therapy.
• Urethral malignancies are a rare but serious complication.

Purpose of the Study:

• To investigate the characteristics and outcomes of urethral secondary malignancies in patients treated with prostate brachytherapy.
• To identify potential risk factors and clinical presentations associated with these rare cancers.

Main Methods:

• Retrospective review of 13 patients with urethral cancer and a history of prostate brachytherapy monotherapy.
• Pathological confirmation of secondary malignancies distinct from primary prostate cancer.
• Evaluation of BRT characteristics, patient demographics, clinical presentation, and disease course.

Main Results:

• Mean time from BRT to RASM diagnosis was 95 months, with a median time to death of 6 months post-diagnosis.
• Most patients (77%) presented with advanced disease (metastases or local progression).
• Common RASM types included sarcomatoid carcinoma, small cell carcinoma, and urothelial carcinoma.

Conclusions:

• Secondary urethral malignancies following prostate BRT are aggressive and associated with poor prognosis.
• Persistent lower urinary tract symptoms and hematuria in patients with a history of prostate BRT should raise suspicion for RASMs.
• Further research is needed to identify factors influencing disease-specific mortality in these patients.